Q-omics provides the consensus-scored MIR342 profile across patient tissues and cancer cell-line models. MIR342 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR342 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MIR342 RNA expression shows 11,025 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, COAD, and THYM as cancer lineages where MIR342 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR342 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR342 survival associations across molecular data types. MIR342 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR342 RNA expression–survival associations across cancer types. High MIR342 expression shows unfavorable associations in UVM, KIRC and LUSC, but favorable associations in SKCM, CESC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR342 RNA expression.
This table summarizes MIR342 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR342. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR342 shows lower tumor expression in COAD, THCA, LUSC and LUAD and higher tumor expression in KIRC and BRCA. The COAD box plot shows higher MIR342 RNA expression in normal versus tumor tissue (log2 FC = −0.382, t-test p < 0.001).
This table shows molecular features associated with MIR342 in patient tissues and cancer cell lines. In patient samples, MIR342 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
